Johnson & Johnson vs Eli Lilly and Co, side by side on the metrics that matter, plus a free AI rating and price targets on each.
On current data, Eli Lilly and Co (LLY) screens stronger across valuation, momentum and analyst consensus. "Better" depends on your thesis and time horizon, run each through the free YN Finance AI Analyzer for a full rating and price targets.
JNJ trades at a P/E of 23.3 versus 53.2 for LLY. Lower isn't automatically better, context matters.
Data via Finnhub, refreshed hourly. Not financial advice, educational purposes only. "Screens stronger" reflects current quantitative metrics, not a recommendation.